Aduhelm Adverse Event Reports Come In, Another Potential Hurdle To Uptake

One patient treated with Aduhelm died who was diagnosed with cerebral edema thought to be ARIA-E, a known risk, Biogen confirmed.

caution tape
Aduhelm early adverse events reports could lead to more caution around prescribing. • Source: Alamy

Biogen, Inc.'s first-in-class beta-amyloid antibody therapy Aduhelm (aducanumab) for Alzheimer's disease has gotten off to a rocky commercial start and initial adverse event reports could add to physician caution about prescribing the medicine.

One death in a patient treated with Aduhelm was reported to the US Food and Drug Administration's Adverse Event Reporting...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category